United Therapeutics (UTHR) Stock Price, News & Analysis

Company Overview

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler. The company also markets Unituxin (dinutuximab) for certain pediatric patients with high-risk neuroblastoma. Its products are sold in the United States and select international markets, subject to regulatory approvals.

Founded in 1996 by Martine Rothblatt, United Therapeutics is headquartered in Silver Spring, Maryland. In addition to its pharmaceutical business, the company is pursuing technologies intended to address the shortage of transplantable organs, including organs from genetically modified animals and bioengineered or manufactured lungs. These efforts are conducted through subsidiaries and affiliated operations such as Lung Biotechnology and Revivicor.

Martine Rothblatt serves as United Therapeutics’ chairperson and chief executive officer. The company’s research and development activities span pulmonary medicine, organ transplantation, xenotransplantation and regenerative medicine, supporting its broader mission of extending and improving human life.

Key Stats

• Today's Range: $498.20 to $509.79
• 50-Day Range: $487.61 to $563.70
• 52-Week Range: $395.00 to $609.35
• Volume: 61,493 shs
• Average Volume: 491,533 shs
• Market Capitalization: $21.43 billion
• P/E Ratio: 17.91
• Dividend Yield: N/A
• Price Target: $646.00
• Consensus Rating: Moderate Buy

United Therapeutics Stock Analysis - MarketRank™

United Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 31st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

United Therapeutics has a consensus price target of $646.00, representing about 27.5% upside from its current price of $506.82.

Amount of Analyst Coverage

United Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.69%

Earnings Growth

Earnings for United Therapeutics are expected to grow by 12.69% in the coming year, from $26.33 to $29.67 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of United Therapeutics is 18.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Therapeutics is 18.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.78.

Price to Earnings Growth Ratio

United Therapeutics has a PEG Ratio of 2.49. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

United Therapeutics has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.39% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently decreased by 9.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Therapeutics does not currently pay a dividend.

Dividend Growth

United Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.88

News Sentiment

United Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for United Therapeutics this week, compared to 11 articles on an average week.

Search Interest

Only 2 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $213,416,923.00 in company stock.

Percentage Held by Insiders

8.60% of the stock of United Therapeutics is held by insiders.

Percentage Held by Institutions

94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/10/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum: 9/23/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UTHR
• CIK: 1082554
• Web: www.unither.com
• Phone: (301) 608-9292
• Fax: 301-608-9291
• Employees: 1,400
• Year Founded: 1996

Price Target and Rating

• Average Price Target for United Therapeutics: $646.00
• High Price Target: $735.00
• Low Price Target: $515.00
• Potential Upside/Downside: +29.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $27.95
• Trailing P/E Ratio: 17.87
• Forward P/E Ratio: 18.99
• P/E Growth: 2.49
• Net Income: $1.33 billion
• Net Margins: 41.56%
• Pretax Margin: 49.87%
• Return on Equity: 20.18%
• Return on Assets: 17.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: $3.18 billion
• Price / Sales: 6.74
• Cash Flow: $33.11 per share
• Price / Cash Flow: 15.10
• Book Value: $164.81 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 42,890,000
• Free Float: 39,202,000
• Market Cap: $21.44 billion
• Optionable: Optionable
• Beta: 0.56